Market closedNon-fractional
Clearside Biomedical/CLSD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Clearside Biomedical
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Ticker
CLSD
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Alpharetta, United States
Employees
30
Website
clearsidebio.com
CLSD Metrics
BasicAdvanced
$84M
Market cap
-
P/E ratio
-$0.55
EPS
2.36
Beta
-
Dividend rate
Price and volume
Market cap
$84M
Beta
2.36
Financial strength
Current ratio
6.07
Quick ratio
5.942
Long term debt to equity
-203.535
Total debt to equity
-203.535
Interest coverage (TTM)
-2.65%
Management effectiveness
Return on assets (TTM)
-37.50%
Return on equity (TTM)
365.97%
Valuation
Price to revenue (TTM)
8.554
Price to book
-3.61
Price to tangible book (TTM)
-3.61
Price to free cash flow (TTM)
-3.528
Growth
Revenue change (TTM)
758.94%
Earnings per share change (TTM)
-4.13%
3-year revenue growth (CAGR)
30.18%
3-year earnings per share growth (CAGR)
6.43%
What the Analysts think about CLSD
Analyst Ratings
Majority rating from 6 analysts.
CLSD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
-96.83%
Net income
-$12M
143.75%
Profit margin
-5,850.00%
7,578.17%
CLSD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.15
-$0.08
-$0.17
-
Expected
-$0.14
-$0.16
-$0.09
-$0.14
-$0.14
Surprise
5.88%
-3.23%
-8.57%
23.55%
-
CLSD News
AllArticlesVideos
Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)
Seeking Alpha·2 days ago
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
GlobeNewsWire·4 days ago
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Clearside Biomedical stock?
Clearside Biomedical (CLSD) has a market cap of $84M as of July 27, 2024.
What is the P/E ratio for Clearside Biomedical stock?
The price to earnings (P/E) ratio for Clearside Biomedical (CLSD) stock is 0 as of July 27, 2024.
Does Clearside Biomedical stock pay dividends?
No, Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Clearside Biomedical dividend payment date?
Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders.
What is the beta indicator for Clearside Biomedical?
Clearside Biomedical (CLSD) has a beta rating of 2.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Clearside Biomedical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.